Main goal of the project
The aim of iConsensus is to develop an integrated control and sensing platform to improve mammalian cell cultivation for biopharmaceutical purposes.
Animal cell technology is widely used in the development and manufacturing of biopharmaceuticals, vaccines, and advanced therapies. The quality of these products is determined by the quality of the cell culture. The iConsensus consortium is developing an integrated platform with analytical methods to monitor, control, and improve cell cultivation. By combining all sorts of control and sensing technologies, the aim is to achieve faster, safer, and more cost-effective production processes.
iConsensus is funded through the Innovative Medicines Initiative 2 (IMI2) Joint Undertaking and is listed under grant agreement number 777397. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).